Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2025
Capivasertib in combination with fulvestrant for the treatment of patients with advanced, hormone receptor positive, HER2 negative breast cancer after endocrine treatment
14 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 13 Jan 2025
Marstacimab for the treatment of patients 12 years of age and older with severe haemophilia A or severe haemophilia B
13 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 10 Jan 2025
Tebentafusp for the treatment of patients with advanced uveal melanoma
9 January 2025 - NICE has published final evidence-based recommendations on the use of tebentafusp (Kimmtrak) for the treatment of ...
Posted by Michael Wonder on 03 Jan 2025
Population health impact of new drugs recommended by NICE in England during 2000–20: a retrospective analysis
4 January 2025 - Health systems experience difficult trade-offs when paying for new drugs. In England, funding recommendations by NICE for ...
Posted by Michael Wonder on 01 Jan 2025
Tarlatamab approved to treat adult patients with small cell lung cancer
31 December 2024 - The MHRA has today approved the medicine tarlatamab (Imdyllytra) to treat adult patients with small cell lung ...
Posted by Michael Wonder on 01 Jan 2025
Sotatercept approved to treat adult patients with pulmonary arterial hypertension
27 December 2024 - The MHRA has approved the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension. ...
Posted by Michael Wonder on 28 Dec 2024
What price is society willing to pay for new drugs?
12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...
Posted by Michael Wonder on 23 Dec 2024
Over 1,000 people with advanced breast cancer set to benefit from new once a day tablet
19 December 2024 - We’ve issued final draft guidance recommending a new once a day tablet that is set to benefit ...
Posted by Michael Wonder on 22 Dec 2024
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
20 December 2024 - For the first time, NICE has recommended an innovative new treatment to help stop babies, children and ...
Posted by Michael Wonder on 22 Dec 2024
Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy
20 December 2024 - The MHRA has today granted a conditional marketing authorisation for the medicine givinostat (Duvyzat) to treat Duchenne ...
Posted by Michael Wonder on 18 Dec 2024
Ublituximab for the treatment of patients with relapsing multiple sclerosis
18 December 2024 - NICE has published final evidence-based recommendations on the use of ublituximab (Briumvi) for the treatment of ...
Posted by Michael Wonder on 18 Dec 2024
What is NICE’s severity modifier?
15 December 2024 - A guide to the severity modifier and how it is leading to more positive recommendations overall from ...
Posted by Michael Wonder on 16 Dec 2024
Should NICE’s cost effectiveness thresholds change?
13 December 2024 - We explore the on-going debate around NICE’s cost effectiveness thresholds and what the future holds. ...
Posted by Michael Wonder on 13 Dec 2024
UK MHRA grants innovation passport designation to ILiAD Biotechnologies BPZE1 next generation intranasal pertussis vaccine
4 December 2024 - ILiAD Biotechnologies today announced that the UK MHRA has granted Innovation Passport designation to BPZE1, the leading ...
Posted by Michael Wonder on 12 Dec 2024
Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced oesophageal squamous cell cancer
11 December 2024 - NICE is unable to make a recommendation on the use in the NHS of toripalimab (Loqtorzi) in ...